Category Archives: Pharmacogenomics

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/xp9wx4/pharmacogenetics_a) has announced the addition of John Wiley and Sons Ltd's new book "Pharmacogenetics and Individualized Therapy" to their offering.

The One-Stop Reference To Pharmacogenetics And Its Impact On Pharmaceuticals, Therapeutics, And Clinical Practices

Pharmacogenetics and Individualized Therapy offers thorough coverage of the study of the genetic determinants of drug response at the single gene leveland its impact on pharmaceuticals, therapeutics, and clinical practice. Providing an overview of the molecular basis of pharmacogenetics, the book helps readers understand the implications of genetic variability on pharmacokinetics and pharmacodynamics, as well as other aspects such as adverse drug reactions. Providing coverage of specific disease areas, including cardiovascular concerns, cancer and asthma/COPD, transplantation, and pain medication, the book also looks at the clinical practices, along with the psychiatric and ethical issues that have come to dominate conversation about pharmacogenetics.

The technological applications of pharmacogenetics, including genotyping, drug disposition (metabolism and enzymes), and the impact of this research on the pharmaceutical industry and regulatory matters are all addressed in chapters by internationally recognized leaders from both academia and industry.

Including chapters on specific therapeutic areas and clinical aspects, Pharmacogenetics and Individualized Therapy helps readers, whether they're students or researchers, to understand the implications of genetic variability on pharmacokinetics and pharmacodynamics.

Authors

ANKE-HILSE MAITLAND-van der ZEE, PhD, is Associate Professor of Pharmacogenetics

Pharmacogenomics at Utrecht University, the Netherlands.

ANN K. DALY, PhD, is Professor of Pharmacogenetics at Newcastle University, UK.

Read the rest here:
Research and Markets: Pharmacogenetics and Individualized Therapy

DUBLIN--(BUSINESS WIRE)--

Dublin - Research and Markets (http://www.researchandmarkets.com/research/7m2ls7/european_molecular) has announced the addition of Frost & Sullivan's new report "European Molecular Diagnostics Markets" to their offering.

This Frost & Sullivan research service titled European Molecular Diagnostics Markets provides a comprehensive analysis of key challenges, drivers, and restraints as well as recent venue forecasts. It also examines major trends and initiatives in the molecular diagnostics market. The research covers oncology, genetic diseases, infectious diseases and pharmacogenomics segments.

Market Overview

Automation to Play Important Role in Expansion of Molecular Diagnostics Markets

The potential for enhanced clinical efficiency and reduced costs is fuelling the interest of healthcare stakeholders in personalised and preventive medicine. Molecular diagnostics is a vital tool to support this trend. Available molecular diagnostics technologies can detect diseases at very early stages and help monitor the efficacy of therapies being used in disease treatment. Technology advances, paralleled by the decreasing cost of automated systems, will boost market prospects, notes the analyst of this research. Automation, in particular, will play an increasingly important role in market expansion.

Many molecular diagnostic methods were historically based on steps of manual pipetting. Automated devices are nowadays replacing them and offer numerous advantages. These include faster turn-around time (TAT), manipulation of smaller volumes of liquids as well as more accurate and quantifiable results, compared to manual methods. Automation is currently of interest mostly among large diagnostic laboratories, but it is expected that, over time, automated systems will also be available at smaller laboratories, remarks the analyst. In small and medium-sized laboratories, if automation is implemented at all, it is likely to be based on single function automated devices rather than fully automated, comprehensive systems. However, automation of molecular diagnostics is still considered to be insufficient. This is especially the case in sample preparation and nucleic acid extraction, where the majority of work is performed manually. This leads to prolonged TAT, which is a challenge, especially when immediate results are required.

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market segments in this research:

- Oncology

Go here to see the original:
Research and Markets: European Molecular Diagnostics Markets

NEW YORK, June 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition

http://www.reportlinker.com/p0203691/Outsourcing-in-Drug-Discovery-The-Contract-Research-Organization-CRO-Market-5th-Edition.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a target protein or nucleic acid in a way that is useful for treatment of disease. The process by which molecules are identified for their therapeutic value involves synthesis and analysis of many derivatives of the original leads. There are several steps in the drug discovery process including hit confirmation, lead generation, lead optimization, and other studies. Drug discovery is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will actually yield products that achieve regulatory approval by the Food & Drug Administration (FDA).

Since the last edition of Kalorama's Report on the outsourcing of discovery of novel compounds in the pharmaceutical industry, the industry has seen dramatic change. Pharmaceutical companies facing cutbacks in R&D budgets and new demands for novel products need to outsource aspects of their operations. Core functions once kept in-house such as the discovery of potential new drugs are now commonly outsourced. Kalorama Information's Outsourcing in Drug Discovery captures this trend, offering unparalleled coverage of the drug discovery outsourcing market. It presents viewpoints from both customers and suppliers. Segments, size, and growth of the market are presented. The trend toward the increased use of offshore suppliers in China, India, Russia and Eastern Europe is covered in detail. The report also provides profiles of 23 suppliers, representative of those active in this market.

Segments covered in this report with market size estimates include:

In addition to market data and forecasts, the report covers issues such as:

This report provides an in depth look into the trends that have shaped the drug discovery outsourcing market today, and details the current and future global market.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, science, medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical, biotechnology and contract research organizations included marketing directors, division managers, and product representatives.

CHAPTER ONE: EXECUTIVE SUMMARY

View original post here:
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition

NEW YORK, June 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Leading Anti-Cancer Drugs and Associated Market 2012-2022

http://www.reportlinker.com/p0819459/Leading-Anti-Cancer-Drugs-and-Associated-Market-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Report Details

Cancer treatments - discover which products have greatest potential

Where are cancer-treating drugs heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions.

This study investigates leading drugs to treat human cancers. It lets you assess potential sales trends at world market, therapeutic submarket, product and national level to 2022.

How will 25 leading products - including Avastin, Rituxan, Herceptin and Glivec/Gleevec - perform from 2012? See potential revenues and other information. The study also assesses eight recently approved drugs.

Our investigation gives you business research and analysis with sales forecasts. You also see forecasting of five submarkets to 2022, finding potential revenues:

Traditional antineoplastic agents

Read more here:
Leading Anti-Cancer Drugs and Associated Market 2012-2022

CARLSBAD, Calif., June 1, 2012 /PRNewswire/ --Life Technologies Corporation (LIFE) will exhibit platforms for companion diagnostic development and products ideal for basic, translational and clinical cancer research during the American Society for Clinical Oncology (ASCO) Annual Meeting 2012, taking place June 1 June 5, in Chicago, Illinois. In addition, several of the company's customers will present clinical research findings obtained with Life's sequencing technologies.

"Life Technologies offers platforms across the spectrum of genomics and proteomics that can be utilized in companion diagnostic development," said Ronnie Andrews, president of medical sciences at Life Technologies. "We share with our pharma partners a dedication to the movement toward personalized treatments based on the specific defects driving cancer in each individual patient."

In October 2011, Life announced a partnership with GlaxoSmithKline to develop a companion molecular test for a GSK candidate cancer immunotherapy.

Presentations:

AmpliSeq panels accurately identify more than 700 mutations in patient samples Marilyn Li, Ph.D., professor of molecular and human genetics and director of the Cancer Genetics Lab at Baylor College of Medicine, will present a poster demonstrating use of the Life Technologies Ion AmpliSeq cancer panels to sequence 12 archived tumor research samples including FFPE, bone marrow and cell line samples. The authors report that the panel accurately identified all known mutations previously detected using Pyrosequencing or Sanger sequencing and was sensitive enough to detect mutations at frequencies as low as 5% with 99% confidence. The poster will be presented June 4, Monday afternoon from 1:15 to 5:15.

AmpliSeq panels validated in CLIA lab with rapid turn-around for tumor sample sequencing Christopher Corless, M.D., Ph.D., chief medical officer of the Knight Diagnostic Laboratories at Oregon Health & Science University's Knight Cancer Institute, will present results using the Ion Torrent (Life Technologies) AmpliSeq Cancer Panel in a CLIA-licensed/CAP-certified setting. Forty-five FFPE tumor samples were sequenced, and the results matched those obtained via previous mass spec-based genotyping and revealed an additional 27 new mutations. Preliminary data from a custom AmpliSeq GI Stromal Tumor (GIST) panel will also be shown. The poster will be presented June 4, Monday afternoon from 1:15 to 5:15.

Featured Products:

Life Technologies offers cancer researchers the ability to detect mutations in cancer-associated genes using both PCR and sequencing platforms.

Ion Personal Genome Machine (Ion PGM) and Ion Proton Between the benchtop Ion PGMSequencer and the benchtop Ion ProtonSequencer, the Ion Torrent technology can cover any application. The Ion PGMSequencer is ideal for sequencing genes, small genomes, panels of genes, or performing gene expression profiling, and its speed, simplicity and scalability also make it an ideal platform to extend into diagnostics.

The Ion ProtonSequencer is ideal for sequencing both exomes regions in the DNA that code for protein and human genomes. The Ion ProtonI Chip, ideal for sequencing exomes, will be available mid-2012. The Ion ProtonII Chip, ideal for sequencing whole human genomes, will be available six months later. In addition, the Ion ProtonOneTouchsystem automates template prep and a stand-alone Ion ProtonTorrent Server performs the primary and secondary data analysis.

See the original post:
Life Technologies Showcases Leading Technologies for Companion Diagnostic Development, Cancer Research at the ASCO ...

ROCHESTER, N.Y.--(BUSINESS WIRE)--

ACM Global Central Lab, the central laboratory that continually defines the customer-service standard with its flexible approach, is pleased to announce that Mark Engelhart has joined the executive management team as chief commercial officer. Engelhart will be responsible for leading ACM Globals business development, proposals and contracts, marketing and sales activities worldwide.

Prior to joining ACM Global, Engelhart was chief commercial officer at Cryoport, Inc. a provider of leading-edge cold chain logistics services. His experience also includes serving in varying sales and marketing management and operations roles at leading pharmaceutical companies, including Bayer and Abbot Laboratories. Engelhart has also held the role of vice president of global sales and marketing at Covance Laboratory, Quest Diagnostics Clinical Trials division and Esoterix Clinical Trials Services.

We are extremely pleased to have Mark join ACM Global, said Angela J. Panzarella, president of ACM Global Central Lab. Mark is a highly accomplished senior executive with deep experience in sales, marketing, strategy, and global commercial operations for central laboratory services and clinical trials support services, and will be a valuable addition to our executive team.

ACM Global will be on hand to discuss the latest trends in clinical research lab testing at PCMG Annual Conference, June 13-15 at the Pine Cliffs Hotel in Portugal and at the 48th Annual DIA Meeting, June 24-28 in Philadelphia.

About ACM Global Central Lab

ACM Global Central Lab offers a flexible approach and a focus on precision to keep clinical research studies on schedule. ACM Globals services extend to more than 60 countries with all tests conducted and managed from central lab facilities with seamless data management providing a single database. The organization performs 14 million tests each year, featuring more than 1,500 individual tests spanning all medical disciplines, including pathology, microbiology, flow cytometry and pharmacogenomics. Combining comprehensive safety, efficacy and pathology testing from a single lab ensures clients receive consistent, analyzable test results with faster and cleaner reporting.

For more information, visit http://www.acmgloballab.com, our Central Labs in Focus blog or call +1 866 405 0400.

See the rest here:
ACM Global Central Laboratory Appoints Mark Engelhart as Chief Commercial Officer